Anabolic therapies.
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calcium-regulating hormone similar to PTH.
Lane
Nancy E
NE
Aging Center, Medicine and Rheumatology, University of California at Davis Medical Center, 4800 2nd Avenue, Suite 2600, Sacramento, CA 95817, USA. nancy.lane@ucdmc.ucdavis.edu
Silverman
Stuart L
SL
D048868:Adaptor Proteins, Signal Transducing; D019485:Bone Morphogenetic Proteins / Q000502:physiology / Q000627:therapeutic use; D016503:Drug Delivery Systems; D005819:Genetic Markers / Q000502:physiology; D006801:Humans; D010006:Osteoblasts / Q000187:drug effects / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000502:physiology / Q000627:therapeutic use*; D044162:Parathyroid Hormone-Related Protein / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use
D048868:Adaptor Proteins, Signal Transducing; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; D010281:Parathyroid Hormone; D044162:Parathyroid Hormone-Related Protein; D011994:Recombinant Proteins; C422903:SOST protein, human